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Abstract The M-potassium current was inhibited by bath appli- 
cation of 100 ctM ATP, 10 nM hradykinin, 100 nM angiotensin 
II and 100 nM endothelin 1 as well as by 10 ~M acetylcholine 
in an ml-muscarinic acetylcholine r ceptor-transformed NG108- 
15 cell line. The inhibition of M-current was attenuated in cells 
pretreated with 5 mM streptozotocin for 5-15 h and restored by 
simultaneous incubation with 5 mM nicotinamide. The results 
suggest hat signal transduction from these five different recep- 
tors to M channels hares a common pathway which is susceptible 
to a streptozotocin-induced decrease in cellular NAD + content. 
Key words: K + current; Signal transduction; Second 
messenger; NAD+; Neuroblastoma x glioma hybrid cell 
2.2. Electrophysiological recordings 
Currents were measured at 35°C by the whole-cell patch-clamp 
method as described previously [11]. Patch electrodes were filled with 
a 90 mM K-citrate solution whose composition is given by Robbins et 
al. [18]. The electrode resistance was about 2-5 MD. Cells were super- 
fused with 10 mM Hepes-buffered DMEM with or without agonists. 
The method of measuring M-current was described previously [ll]. 
Some of the data was processed by p-Clamp. 
2.3. Materiab 
Bradykinin, angiotensin II and human endothelin 1 were purchased 
from Peptide Research (Osaka, Japan). ATP and ACh were purchased 
from Sigma (St Louis, MO). 
3. Results 
1. Introduction 
The voltage-dependent potassium M-current leads to up- 
modulation of the membrane xcitability of neuronal cells, 
when inhibited by muscarinic agonists [1]. The M-current inhi- 
bition is elicited by a number of different transmitters, including 
bradykinin [10], ATE UTP [7], angiotensin II [19], endothelin 
1 [15], substance P and LHRH [13]. However, the signal 
transduction pathway from these receptors to M channels i not 
yet clear [5,18]. Recently, we have shown that the muscarinic 
acetylcholine receptor (mAChR)-M channel coupling is par- 
tially blocked in streptozotocin-treated NG108 15 hybrid cells 
in which the cellular NAD ÷ concentration is reduced, and that 
the M-current is slowly decreased by intracellular injection of 
cADP ribose (cADPR), a product of NAD + formed by ADP 
ribosyl cyclase [11]. Therefore, we have proposed that NAD + 
or NAD + metabolites may be involved in the signal pathway 
from mAChRs to M channels [11]. Here, we present data show- 
ing that the M-current inhibition induced by five different ag- 
onists is blocked to the same extent in streptozotocin-treated 
NG108-15 cells, supporting this hypothesis. 
2. Materials and methods 
2.1. Cell culture 
NGPMI 27 cells, a subclone of ml-mAChR-transformed NG108 
15 cells [9], were used. Cells were maintained in culture and differen- 
tiated with 0.25 mM dibutyryl cAMP for 12-21 days as described 
previously [10]. 5 mM streptozotocin a d/or nicotinamide were added 
in serum-containing Dulbecco's modified Eagle's medium (DMEM), in 
which the cells were incubated for 5-15 h before electrophysiological 
recordings [11]. 
Bath perfusion with the maximum dose of five different ag- 
onists (100/IM ATE 10 nM bradykinin, 100 nM angiotensin 
II, 100 nM endothelin 1and 10]tM ACh) of NGPM1-27 cells, 
voltage-clamped at a depolarized membrane potential of -20 
mV, produced a steady inward current ranging from 0.2 to 1.5 
nA as previously described in this cell line [9,11,18] and in the 
parental NG108-15 cells [7,10,15]. Fig. 1A shows the time 
course of ATP-induced current changes as a representative 
example of all the agonist-induced inward current. These in- 
ward currents were associated with an inhibition of the M- 
current in response to a hyperpolarizing step as shown in five 
cases of ATP (Fig. 1B), bradykinin (Fig. 2A), angiotensin II
(Fig. 2B), endothelin 1 (Fig. 2C) and ACh (Fig. 2D). The 
amplitude of the M-current inhibition (calculated from (x-y)/  
x x 100, where x and y are shown in Fig. I C) was on average 
41 + 3.1% (mean + S.E.M., n = 14) for ATE 43 + 6.1% (n = 9) 
for bradykinin, 37+3.6% (n - - l l )  for angiotensin II, 
37 + 5.3% (n = 5) for endothelin 1 and 57 + 4.8% (n = 6) for 
ACh, respectively (Table 1). 
The same set of agonists were applied to NGPM1-27 cells 
pretreated with 5 mM streptozotocin for 5 15 h. The inward 
current and associated M current inhibition induced by the five 
agonists were attenuated significantly (P < 0.05 or < 0.01, Table 
1) as shown in Fig. 3A E. The mean inhibition of M-current 
was reduced to 22% of the control response for ATE 44% for 
bradykinin, 19% for angiotensin II, 41% for endothelin 1 and 
30% for ACh, respectively (streptozotocin/controlx 100 in 
Table 1). As expected, this inhibitory effect of streptozotocin 
on the agonist-induced M-current inhibition was restored by 
simultaneous incubation with 5 mM nicotinamide. 5 mM ni- 
cotinamide alone had a small but negligible ffect (Table 1). 
4. Discussion 
*Corresponding author. Fax: (81) (762) 34 4236. The results show that functional P2u ATP [7,12,14,16] B2 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)0 1 51 6-7 
H. Higashida et al./FEBS Letters 379 (1996) 236~38 237 
A ATP 
I I 
C 
a lIIiliIllllllIlililIllllll b •••••••••••••••••I•••••••I••••••••••••I•I••••••I•••I••I••••I•I•I•I••••iI•I••••••• ~ 
30s  o 
B 
a cont b +ATP c wash 
-20 
v -'1 1 -1 F -  "7 I--4o 
mV 
, 
0.5s  
C cont +agonist  
. ,  / . . -  
I .  ~ .  x ~. .my 
Fig. 1. ATP-induced inward current and M-current inhibition in an 
ml-transformed NGPMl-27 cell. The untreated control cell was held 
at -20 mV to activate M-current and stepped to -40 mV for 1 s every 
30 s to deactivate it. (A) ATP (100 #M) was applied by bath perfusion 
for the duration indicated by the bar. ATP produced asustained inward 
current (I). Repetitive inward transients were evoked by such voltage 
steps. The dashed line shows the initial current level from which bath 
application of ATP induced an inward (downward) shift of holding 
current. (B) Expanded records of voltage steps (V) and current ran- 
sients (I). The currents were recorded before (a), during perfusion with 
100 ,uM ATP (b) and after washing out it (c) at the indicated times in 
(A). (C) The diagram shows the measured M-current (IM) in two current 
traces obtained before (x) and after (y) agonist perfusion. 
bradykinin [10,17,20,21], AT2 angiotensin [24]  and endothelin 
[6,8,15,22] receptors, which are expressed in parental  NG108 
15 cells, are present in NG108-15 cells overexpressing m 1 mA- 
ChRs and that they elicit an essentially equal amount  of the 
M-current inhibition. Furthermore,  the results suggest hat the 
a b 
cont agonist 
v- I  I - -  - I  J 
C 
wash mV 
-20 
--I I -40 
I BK 
r -  
i 
F" 
I 
AT II 
ET I 
c - . . r  - . . . . . . .  I 
ACh 
D- -  L --- r <: 
O 
0.5 s 
Fig. 2. Four different agonists-induced inward current and inhibition 
of M-current in an untreated control NGPM1 27 cell. The same cell 
shown in Fig. 1 was held at -20 mV to activate M-current and stepped 
to -40 mV for 1 s every 30 s to deactivate it. Current races evoked by 
such voltage steps are shown. Currents were obtained before (a), during 
perfusion with each agonist (b) and after washing out them (c). Agonists 
used are 10 nM bradykinin (BK, A), 100 nM angiotnsin II (AT II, B), 
100 nM endothelin 1 (ET 1, C), and 10 #M ACh (D). 
signal pathways from these five receptors, which are originally 
reported to couple to phosphol ipase C [4,6,8,12,14,15,17,20,21], 
to M channels merge into one, because M-current inhibit ion 
was susceptible to streptozotocin treatment and was restored 
by an addition of nicotinamide. Our previous measurement 
shows that in streptozotocin-treated NGPM1 27 cells, cellular 
NAD ÷ content is reduced to about 40-50% of the control level 
Table 1 
Agonist-induced M-current inhibition in NGPM1 27 cells under various conditions 
Percentage inhibition of M-current (n) 
Agonist Control Streptozotocin Streptozotocin + Nicotinamide Nicotinamide 
ATP 41 + 3.1 (14) 9.1 + 5.5** (10) 33 _+ 5.6 (5) 51 +_ 5.5 (4) 
Bradykinin 43 + 6.1 (9) 19 + 6.2* (6) 38 + 7.2 (4) 50 _+ 8.4 (4) 
Angiotensin II 37 + 3.6 (11) 7.0 + 4.7** (4) 52 + 2.8 (3) 41 _+ 4.2 (3) 
Endothelin 1 37 + 5.3 (5) 15 + 4.6* (8) 27 + 4.0 (4) 38 + 4.5 (5) 
ACh 57 + 4.8 (6) 17 + 9.8* (5) 46 + 9.0 (5) 48 _+ 6.1 (4) 
M-current was recorded as described in Fig. 1. Mean percentage inhibition of M-current was calculated from (xy) /x  x 100, where the amplitude 
of M-current before (x in Fig. 1C) and after (y in Fig. 1C) bath application of 100 #M ATE 10 nM bradykinin, 100 nM angiotensin II, 100 nM 
endothelin 1and 10 ,uM ACh. Currents were recorded in untreated control cells or cells treated for 5-15 h with 5 mM streptozotocin, with 5 mM 
streptozotocin+5 mM nicotinamide and with 5 mM nicotinamide, respectively. Values are the mean + S.E.M. Number of cells tested is indicated 
in parentheses. *P < 0.05 and **P < 0.01 from control cells. 
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Fig. 3. Five different agonists-induced inward current and inhibition of 
M-current in streptozotocin-treated NGPM1-27 cells. Currents were 
recorded as shown in Figs. 1 and 2 in 5 different cells treated with 5 mM 
streptozotocin for 5 15 h. Currents were obtained before (a), during 
perfusion (b) with 100 pM ATP (A), 10 nM bradykinin (BK, B), 100 
nM angiotnsin II (AT II, C), 100 nM endothelin 1 (ET 1, D) and 10 
#M ACh (E) and after washing out them (c). 
[l 1] and that this level is recovered by simultaneous addition 
of nicotinamide, a precursor of NAD ÷. Thus, it is likely that 
the partial blockade of M-current inhibition induced by the 
four different agonists is closely related to the cellular NAD + 
level as suggested for ml mAChRs. 
It is likely that slow M-current inhibition is mediated by a 
diffusible second messenger(s) [5,9,10,19]. As has been pro- 
posed, suppression of M-current by angiotensin II seems to 
share a common signalling pathway with suppression by mus- 
carinic agonists [19]. Furthermore, cADPR, a NAD ÷ metabo- 
lite, also inhibited M-current in NG108-15 cells [11]. In line 
with this idea, we propose that these five receptors may share 
a common pathway in this cell line. Although it is not yet clear, 
it is possible that cADPR is a common mediator in their down- 
stream pathway. 
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